- Hypertrophic Cardiomyopathy (HCM)
- Vaccines: 2023 Year in Review
- Eyecare
- Urothelial Carcinoma
- Women's Health
- Hemophilia
- Heart Failure
- Vaccines
- Neonatal Care
- NSCLC
- Type II Inflammation
- Substance Use Disorder
- Gene Therapy
- Lung Cancer
- Spinal Muscular Atrophy
- HIV
- Post-Acute Care
- Liver Disease
- Pulmonary Arterial Hypertension
- Biologics
- Asthma
- Atrial Fibrillation
- Type I Diabetes
- RSV
- COVID-19
- Cardiovascular Diseases
- Breast Cancer
- Prescription Digital Therapeutics
- Reproductive Health
- The Improving Patient Access Podcast
- Blood Cancer
- Ulcerative Colitis
- Respiratory Conditions
- Multiple Sclerosis
- Digital Health
- Population Health
- Sleep Disorders
- Biosimilars
- Plaque Psoriasis
- Leukemia and Lymphoma
- Oncology
- Pediatrics
- Urology
- Obstetrics-Gynecology & Women's Health
- Opioids
- Solid Tumors
- Autoimmune Diseases
- Dermatology
- Diabetes
- Mental Health
3 Upcoming Urothelial Cancer Conferences
At this time, two of three conferences have been reverted to a in-person and virtual format. This includes The American Urological Association (AUA) 2021 Annual Meeting and the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting.
Interest and research into urothelial cancer is growing and with that, the number of medical conferences where urothelial cancer will be an important topic. The delta variant of the COVID-19 virus is wreaking havoc with conference planning. A number of groups have pulled back their plans for an in-person meeting and have gone back to a virtual format.
The American Urological Association (AUA) 2021 Annual Meeting
The AUA annual meeting will be held in-person and virtually September 10-13, 2021 from Las Vegas, Nevada, and the program will offer evidence-based medical information for urologists and other healthcare professionals in the field globally, which includes the latest research, new guidelines, and advances in the specialty. Here are some of the topics that will be presented at the conference:
- Robotic surgery
- Interactive cases
- Surgical updates for upper tract urothelial cancer
- Pain management
- Research
- Bladder cancer treatment
- Patient care management
MD Anderson Cancer Center Multidisciplinary Collaborative Cancer Care Conference 2020
This conference was postponed in 2020 and is now scheduled to take place October 16-21, 2021 in Aspen, Colorado. Physicians and other healthcare professionals from all disciplines who treat cancer patients generally attend this conference. The conference agenda will be available soon, and the focus will include diagnosis and management options that improve health outcomes.
Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting
The SITC conference is scheduled for November 10-14, 2021 at the Walter E. Washington Convention Center in Washington D.C. and will include virtual options. Additionally, this is the largest conference to focus solely on cancer immunotherapy that brings together international leaders from academia, regulatory and government agencies, and industry representatives. Conference agenda topics and events include the following:
- CAR T in solid tumors and novel combinations
- Panel discussions
- Tumor immunology
- Cancer vaccines
- Digital medicine
- Clinical trials and research
- Poster presentations
- COVID-19 antibody responses in cancer patients
Meet the Board: Otis Brawley Talks Health, Racial Disparities, Cancer Screenings and More
September 30th 2020This episode of Tuning Into The C-Suite welcomes our first of many episodes part of the new “Meet the Board” podcast series. Listeners will now hear from a member of Managed Healthcare Executive's Editorial Advisory Board once a month at the end of each month. The first guest featured is Physician and former Executive VP of the American Cancer Society, Otis Brawley. Brawley is a Bloomberg Distinguished Professor of Oncology and Epidemiology at Johns Hopkins University.
Listen
Updated SITC Immunotherapy Guidelines for Urothelial Cancer
August 3rd 2021The Society for Immunotherapy of Cancer (SITC) released guidelines based on FDA approved immune checkpoint inhibitors (ICIs) for the treatment of urothelial cancer arising from the bladder and other areas of the urinary tract. The guidelines were based around therapies such as the programmed cell death protein 1 (PD-1) inhibitors Opdivo (nivolumab) and Keytruda (pembrolizumab) and the programmed cell death ligand 1 (PD-L1) inhibitors, Tecentriq (atezolizumab), Bavencio (avelumab) and Imfinzi (durvalumab).
Read More
Integrating Advanced Practice Providers into Oncology Settings for Managing Urothelial Cancer
July 6th 2021According to the American Urological Association, 72.5% of urologists used Advanced Practice Providers in their practice and these healthcare providers performed a variety of procedures such as a cystoscopy (procedure examining bladder lining), which assists in the diagnosis of bladder cancer. Evidence shows patients have demonstrated a growing acceptance of APPs in urology practice settings.
Read More
